DCPrime
DCPrime is a clinical-stage biopharmaceutical company based in Leiden, Netherlands, developing novel cancer immunotherapies based on its proprietary DCOne dendritic cell platform technology.
- Company typePrivate
- Founded2006
- HeadquartersLeiden, Netherlands
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What DCPrime does
DCPrime is a clinical-stage biopharmaceutical company founded in 2006 and headquartered in Leiden, the Netherlands. The company develops novel cancer immunotherapies based on its proprietary DCOne platform technology, which is centered on dendritic cell-based approaches to oncology. Operating with a workforce of 11-50 employees, DCPrime is positioned in the European biotech ecosystem as a specialized developer of cell-based immuno-oncology therapeutics.
The company's core asset is the DCOne platform, the technical foundation for its pipeline of cancer immunotherapy candidates. As a clinical-stage developer, DCPrime's business model is built around advancing candidates through preclinical and clinical development, with the long-term value capture likely dependent on out-licensing, partnership milestone payments, or eventual commercialization of approved therapies. At present, there is no evidence of commercial product sales, recurring revenue, or named customers in the available data. Capital formation has come through a combination of venture rounds led by Van Herk Ventures, a SkylineDx co-investment, a Thuja Capital seed round, and a non-dilutive Horizon 2020 grant from the European Commission — total disclosed funding is approximately $26.5M, with the largest tranche of $18.7M raised in March 2018.
The company is led by a three-person executive team: Erik Manting as CEO, Ada Kruisbeek as Chief Scientific Officer, and Jeroen Rovers as Chief Medical Officer. This structure is consistent with a clinical-development-stage organization rather than a discovery-only operation. DCPrime's primary stakeholders at this stage are its investors, clinical investigators, and prospective pharma licensing partners rather than end patients or prescribing physicians, and its customer base in the traditional commercial sense does not yet exist.
DCPrime firmographics
Firmographics- Name
- DCPrime
- Website
- https://dcprime.nl
- Company type
- Private
- Founded year
- 2006
- Headcount range
- 11–50 employees
- Short description
- DCPrime is a clinical-stage biopharmaceutical company based in Leiden, Netherlands, developing novel cancer immunotherapies based on its proprietary DCOne dendritic cell platform technology.
- Ownership category
- akta.pro rank
DCPrime industry classification
Industry- Product category
- Cancer Immunotherapy
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Dendritic Cell & Other APC-based Therapies (HLAAABAF)
Keywords
Where DCPrime is headquartered
LocationHeadquarters
- HQ city
- Leiden
- HQ country
- Netherlands
- HQ region
- Europe
Markets served
DCPrime business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations
DCPrime product offering
Product offeringCore offering
DCPrime is a clinical-stage biopharmaceutical company that develops novel cancer immunotherapies built on its proprietary DCOne platform technology. The company focuses on dendritic cell-based therapeutic approaches aimed at treating cancer, with drug candidates progressing through clinical trials.
Differentiator
Problem solved
Functional benefit
Products and services
- DCOne Platform-Based Cancer Immunotherapies
Companies that use DCPrime
Customer profileIdeal customer profiles1 record
DCPrime technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
DCPrime partnerships and signals
Strategic signalRecent moves5 records
Expansion highlights3 records
DCPrime competitors and assessment
Company assessmentMarket position
Competitive moat3 records
Key risks4 records
Key highlights6 records
Customer concentration
DCPrime social profiles
Digital presenceDCPrime financial estimates
Financial estimateRevenue estimate
Valuation estimate
DCPrime leadership team
Management profileNumber of profiles
Profiles3 records
DCPrime funding detail
Funding detailFunding overview
Funding rounds5 records
Investors4 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
DCPrime M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about DCPrime
What does DCPrime do?
DCPrime is a clinical-stage biopharmaceutical company that develops novel cancer immunotherapies built on its proprietary DCOne platform technology. The company focuses on dendritic cell-based therapeutic approaches aimed at treating cancer, with drug candidates progressing through clinical trials.
When was DCPrime founded?
DCPrime was founded in 2006. It employs 11 to 50 people.
Where is DCPrime based?
DCPrime is headquartered in Leiden, Netherlands, in the Europe region.
Does DCPrime have an API?
No public API is recorded for DCPrime.
What industry is DCPrime in?
DCPrime's product category is Cancer Immunotherapy. Its primary akta.pro industry code is HLAAABAF, Dendritic Cell & Other APC-based Therapies. Its NAICS code is 541714 and its SIC code is 2834.